Overview

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult Participants

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2027-05-13
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to investigate the safety, tolerability, and pharmacokinetic (PK) profiles of two different cabotegravir formulations in healthy adult participants. The study will initially start with the assessment of Cabotegravir Formulation F. Once the clinical batch of Cabotegravir Formulation G is available, this formulation will be assessed.
Phase:
PHASE1
Details
Lead Sponsor:
ViiV Healthcare